20/MIDAS eval’d MRD-guided consolidatn post 1L IsaKRd in TE NDMM

Post 1L, no 🔼 in MRD- rates for all pts
Tailoring tx to MRD post 1L may not ➡️ MRD-
If respond to 1L tx may not need tandem SCT to reach MRD-; cont anti-CD38 &PI

🤔High # pts w t(11;14): impact time to MRD- results?

17/📣GMMG-CONCEPT ASCO2025 update, TE pts:
73.2% MRD- post-consolidatn; p=1.91x10-13
86.8% MRD- @ any time
58.4% MRD- ≥CR
40.6% retained ≥2yr sust MRD-

Med follow-up: 43m(0-90.2m)
mPFS: 72.8m
5yr OS: 72%
6yr OS: 69%
⬆️2yr sustMRD-, ⬆️PFS, 69% OS @ 6yr

IsaKRd:🆕SOC for HRNDMM

11/Do results w isa show similar trends?

IMROZ🔑trial
IsaVRd ➡️ IsaRd v VRd ➡️ Rd in TIE pts w NDMM

👉IsaVRd ➡️↓time to MRD-: 14.7 v 32.8m
👉↑ PFS @ 60m: 63.2 v 45.2%; HR: 0.60; P<0.001
👉↑ CR: 74.7% v 64.1%; P=0.01
IMROZ results support IsaVRd as 🎉 🆕 SOC for TIE #NDMM pts

10/ CEPHEUS🔑 trial in TIE & SCT-deferrd pts
DVRd ➡️ deeper, more durable MRD- rate

TIE cohort:
👉Overall MRD- 63.2 v 41.4%
👉Sustained MRD @ ≥12m 48.7 v 26.3%; P<0.0001
👉CR 81.2 v 61.6%; P<0.0001
👉HR 0.57, 95% CI 0.41-0.79; P=0.0005
↓D/C rate w quad

🎉DVRd new SOC for TIE NDMM🎉

7/⚡️GMMG-HD7 #ASCO25 update w/ PFS benefit in all quad recipients

↑CR 43.5% w IsaVRd v 34% w VRd
↑MRD- rate 66.2% w quad v 47.7% w triplet
👉PFS at 3yr benefit: 83% v 75% w/IsaVRd v VRd
↑MRD- regardless of maint v MRD+ (HR 0.61; P=0.002)
🔮Maintenance w Isa-len v len is on-going

5/ PERSEUS #ASCO25: sustained MRD- in pts on quad maintenance median follow-up of 47.5m

👉 ↑ sustMRD- at ≥24m w DVRd v VRd: 55.8 v 22.6%
👉 Pts w ≥12m sustMRD-: ↑ 48m PFS, regardless of tx
👉 Only 3.1% progression at 18m w DVRd v 6.8% VRd
🔑 DVRd ➡️ 2.5x ⬆️ ≥24m sustMRD- & ½ progression risk at ≤18m tx

4/💃Quads are taking center stage in NDMM
Let’s look @ the📈 on quad tx

PERSEUS ~🔑 trial: SQ dara➕VRd ➡️ ↑outcomes in TE pts

👉↑PFS @ 48m 84.3 v 67.7%; HR: 0.42; P<0.001
👉↑MRD- rate 75.2 v 47.5%; P<0.001
👉↑CR rate 87.9 v 70.1%; P<0.001
🎉 🆕 SOC ~ quad instead of triplet 🎉

2/ Before we jump in, a few disclosures & important links🔗

1️⃣📖#CME info bonumce.short.gy/NDMM-TW1-CME
2️⃣Take the pre-survey 👉bonumce.short.gy/NDMM-TW1-Pre
3️⃣Get the latest NDMM quad tx efficacy data w/ 🧵👇
4️⃣🏆Claim🆓CME bonumce.short.gy/NDMM-TW1-Post

Now, let's get started!